National Eye Institute announces AREDS2 Results for Macular Degeneration

The AREDS2 results were published May 5, 2013 by the National Eye Institute in the Journal of the American Medical Association. The publication of these results can be found at http://tinyurl.com/areds2.

STUDY HIGHLIGHTS:

1. A modified AREDS Formula with both Lutein and Zeaxanthin, but without beta-carotene, was 18% more effective than AREDS1.
2. Lutein and Zeaxanthin absorption improved when beta-carotene was removed from the formula.
3. Beta carotene was again proven to increase lung cancer in former smokers.
4. No significant decrease in benefit was found comparing 25 mg versus 80 mg of Zinc oxide.
5. Omega 3 fish oils were not found to be beneficial in Grade 3 and 4 macular degeneration patients.

Men are especially advised to take a supplement such as VisiVite AREDS2 Plus+ Formula that contains selenium, based on the results of the United States Government’s Selenium and Vitamin E Cancer Prevention Trial. VisiVite AREDS2 Plus+ Gold Formula contains 400 IU Vitamin E and 200 mcg Selenium, just as found in that study, which found the following risk of prostate cancer in healthy man taking:

- Vitamin E 400 IU risk: 1.6 (higher risk)
- Selenium 200 mcg risk: 0.8 (lower risk)
- Vitamin E plus Selenium risk: 0.4 (much lower risk)

VisiVite AREDS2 Plus+ Gold Formula contains high levels of both Lutein and Zeaxanthin, as well as Vitamins C and E, Zinc and Copper, just as recommended by this latest research. And compared with AREDS2, VisiVite AREDS2 Plus+ Gold Formula contains:

- 50% more Lutein
- 138% more Zeaxanthin